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mutations in SCN1A in 11 of 14 patients with purported 
vaccine encephalopathy.9
What is the reason for the temporal proximity of 
vaccination and onset of the epileptic encephalopathy? 
Is the SCN1A mutation a predisposing factor waiting to 
be triggered by fever or other stress? Probably so. In fact, 
as early as 2000, Nieto-Barrera and colleagues12 noted 
that more than 50% of patients with SMEI had their fi rst 
seizure after DPT vaccination. 
Should vaccination be continued in children diagnosed 
with SMEI, or for that matter with similar epileptic 
encephalopathies? This question awaits further study, 
but also needs careful consideration of each patient’s 
particular clinical circumstances. Complications of 
naturally contracted infections are much higher than 
those associated with vaccination (63% vs 7·2%), and 
prophylactic antipyretic treatment in many cases can 
eff ectively prevent the common reactions to vaccination.13 
In any case, a switchover to acellular pertussis is clearly 
warranted where this has not yet occurred.
The study by Berkovic and collaborators9 not only 
shows the novel association of SCN1A mutations with 
vaccine encephalopathy, but also helps to demystify 
the isolated association of vaccination and unexplained 
encephalopathy. This should help decrease unwarranted 
avoidance of vaccination and endangerment of children’s 
and public health.
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Are SCNA1 mutations waiting to be triggered by fever or stress?
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Antihypertensives for prevention of Alzheimer’s disease 
For about 25 years hypertension has been recognised as 
a long-term risk factor for Alzheimer’s disease. The latent 
period between the manifestation of hypertension and 
the initial signs of mental deterioration is variable. The 
time lag fi rst established in the Framingham study1 and 
subsequently confi rmed by long-term studies with similar 
design and follow-up was of several decades, between 
hypertension in middle age (about age 50 years) and 
the fi rst signs of cognitive dysfunction some 20 years 
later. With increasingly subtle diagnostic procedures, the 
temporal associations between hypertension and cognitive 
impairment seem to have become clearer.2 Developments 
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of this kind unfortunately seem to escape the awareness of 
most clinicians in both general and specialist medicine.  
Perhaps, the key problem is that most otherwise 
eff ective antihypertensive drugs do not provide a 
common generic guarantee of measurable protection 
against cognitive dysfunction by the lowering of blood 
pressure. Unfortunately, the large comparative prospective 
trials of antihypertensive drugs published over the past 
decade, which we recently reviewed,3 did not incorporate 
cognitive impairment or dementia as a trial endpoint. 
These trials have left us with few data, among which the 
dihydropyridine calcium-channel blocker nitrendipine, 
as used in the Systolic Hypertension in Europe trial,4 
off ered substantial protection against both vascular and 
degenerative dementias over up to 8 years of follow-up.  
The recently reported Cache County Study5 is a realistic 
eff ort to off er some compensation for the missed 
opportunities of the large prospective trials.3 This 
multidisciplinary eff ort sought to establish evidence for 
specifi c cognitive protection by various antihypertensive 
treatments in a population of patients with hypertension 
age 65 years or older in a stable community. The ongoing 
study was started in 1995 (wave 1), including a personal 
interview and an adapted modifi ed mini-mental state 
examination (3 MS). For those unable to participate 
in dialogue, a surrogate questionnaire (IQ CODE) was 
presented to a carer or family member. 3 years later, 
beginning in 1998, the procedure was repeated (wave 
2). Those who then scored below predetermined cut-off  
points on the 3MS or the IQ CODE underwent a highly 
structured neuropsychological assessment. A preliminary 
diagnosis of dementia according to DSM-III-R criteria 
was followed by even more refi ned techniques including 
neuroimaging, and application of NINCDS-ADRDA 
(National Institute of Neurological and Communicative 
Disorders and Stroke and Alzheimer’s Disease and Related 
Disorders Association) criteria to diagnose Alzheimer’s 
disease. Participants without dementia from wave 1 were 
classifi ed according to all antihypertensive drugs currently 
in use. Blood pressure was not taken in all participants, 
but merely in a fully examined subsample of patients. 
Covariables included routine factors, such as age, sex, 
education, cardiovascular illnesses, and the number of 
APOE alleles. 
This vast, but in our view partly unfocused, exploration 
produced the following results.5
 
3308 participants 
without dementia in wave 1 completed wave 2 to a 
degree suffi  cient to assess their cognitive status. Of these, 
185 had dementia, which was diagnosed as Alzheimer’s 
disease in 104 patients. The remaining 81 patients with 
dementia, presumably vascular or mixed dementias, were 
excluded from consideration for unspecifi ed nosological 
reasons. In our opinion, the latter unfortunate decision 
could have wasted important data because degenerative 
and vascular dementia subtypes seem to be confl uent in 
their substrates.6 Hopefully, the researchers will rerecruit 
this lost tribe. 
The researchers reported an impressive gradation 
between the effi  cacies of the diff erent antihypertensive-
drug categories used in their study, in terms of preventing 
Alzheimer’s disease (table). The big surprise here is the 
superior eff ect of potassium-sparing diuretics. It would be 
important to include the eff ect of these diuretics on the 
prevention of vascular dementia to see whether there are 
similar eff ects; this also applies to the apparent equivalence 
between dihydropyridine calcium-channel blockers 
and β-blockers. The rather poor eff ect of angiotensin-
converting enzyme inhibitors came as no surprise to us, 
given the outcome of our earlier meta-analysis.7 
The researchers rightly recommend further 
epidemiological and experimental studies with regard to 
possible explanations of the above results. As far as the 
dihydropyridine calcium-channel blockers are concerned, 
there is already a wealth of experimental studies explaining 
their potential protective mechanisms with regard to 
the prevention of both types of dementia.8 Whether or 
not lowering of blood pressure can prevent Alzheimer’s 
disease and to what extent some antihypertensive drugs 
can provide specifi c protection against neurodegenerative 
dementia, above and beyond blood-pressure lowering, is 
an issue with far-reaching implications for public health. 
Because of the worldwide demographic transition from 
high to low rates of birth and death, dementia is fast 
becoming one of the principal causes of major disability and 
Adjusted HR (95% CI) 
Potassium-sparing diuretics 0·26 (0·08–0·64) 
Dihydropyridine CCBs 0·53 (0·16–1·34) 
β-blockers 0·53 (0·22–1·09) 
Diuretics 0·53 (0·22–1·09) 
ACE inhibitors 1·13 (0·60–1·98) 
HR=hazard ratio; CCB=calcium-channel blocker; ACE=angiotensin converting enzyme. 
Table: Association of Alzheimer’s disease with use of antihypertensive 
drugs 
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mortality.6,9 Medical treatment of established dementia has 
only marginal benefi t and is not cost eff ective. Prevention 
is the only way to turn the tide. Clinical trials must be 
begun to specifi cally address the question of whether drug 
class matters in the prevention of Alzheimer’s disease by 
blood-pressure lowering.9 Observational studies, such as 
the Cache County Study from Utah,5 even when properly 
analysed, are subject to biases originating from reverse 
causality, attrition, and self-selection of participants. Such 
studies are only hypothesis-generating and will never 
provide a defi nite answer.  
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Cholinesterase inhibitors in late-stage  Alzheimer’s disease 
The Swedish Nursing Home Study1 compared donepezil 
with placebo for the treatment of severe Alzheimer’s 
disease in patients living in assisted-care facilities; this 
study off ers an opportunity to think about the use of 
cholinesterase inhibitors in late stages of this disorder. 
Winblad and colleagues used standard outcomes to assess 
the effi  cacy of donepezil: the severe impairment battery 
(SIB), the cognitive measure most appropriate for this 
stage of Alzheimer’s disease; an activity of daily living 
measure modifi ed for severe Alzheimer’s disease (ADCS-
ADL-severe); the neuropsychiatric inventory (the most 
widely used behavioural measure); the mini-mental state 
examination (MMSE), which is not as sensitive to change 
in this disease stage; and a clinical global impression 
of improvement. The primary analysis on a modifi ed 
intention-to-treat population showed signifi cant 
diff erences in favour of donepezil in SIB, ADCS-ADL-
severe, and the MMSE but not for the neuropsychiatiric 
inventory or clinical global impression of improvement. 
Adverse events were equivalent except for diarrhoea and 
hallucinations, which were more than twice as common 
in patients taking donepezil than in those taking placebo. 
The researchers had predetermined a clinically signifi cant 
treatment diff erence for the two primary outcomes 
(SIB and ADCS-ADL), which was not quite reached at 6 
months, as highlighted in the accompanying editorial by 
David Hogan.2 
Another study comparing donepezil with placebo in 
community-dwelling patients with severe Alzheimer’s 
disease showed benefi ts for all outcomes, including the 
total neuropsychiatric inventory score at 6 months.3 
The inability to detect improvement of behaviour in 
the Swedish Nursing Home Study may be caused by the 
sensitivity of the neuropsychiatric inventory in a nursing-
home setting, the fact that non-family members are 
asked about their perception of the patients’ moods 
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Cholinesterase inhibition in Alzheimer’s disease may need to be tailored to individual patients
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